RT Conference Proceedings
T1 Afatinib plus EGF pathway targeting immunization (EGF-PTI) as first line therapy for EGFR mutant NSCLC: The EPICAL study
A1 Karachaliou, N.
A1 Cardona Zorrilla, A.
A1 Rodriguez-Abreu, D.
A1 Cobo Dols, M.
A1 Reguart Aransay, N.
A1 Viteri, S.
A1 Codony-Servat, J.
A1 Molina-Vila, M. A.
A1 D'Hondt, E.
A1 Rosell, R.
PB Elsevier science inc
SN 1556-0864
YR 2018
FD 2018-04-01
LK https://hdl.handle.net/10668/24379
UL https://hdl.handle.net/10668/24379
LA en
DS RISalud
RD Apr 6, 2025